With various challenges impacting the clinical supply chain, existing models are no longer fit-for-purpose and need to adapt.

Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...

Triomics, an oncology-focused artificial intelligence company, raised $15 million to help automate cancer providers’ workflows. Investors supporting the round include Lightspeed, Nexus Venture ...

Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

Community-based clinical trials hold much promise for modernizing the way we develop new treatments for the patients who need them. Their community-embedded design can improve diversity, increasing ...

Clinical trials are an essential part of medical breakthroughs that help patients, but getting them off the ground and running them is often fraught with challenges. Specifically, qualification, ...

Can you explain what we mean when we discuss “sex and gender diversity” in clinical trials? Sex and gender diversity means moving away from the binary model and embracing a more inclusive approach.

Fred Hutch Cancer Center is committed to inclusivity in clinical trials. We recognize that it is essential to have a wide range of people from different communities participate in clinical trials to ...

What happens to a patient after I refer them to a clinical trial? Do they leave my practice? Referring patients to a clinical trial is similar to referring them to a specialist. They remain your ...